Nabumetone
Product Images NDC 61919-160

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Nabumetone (NDC 61919-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Direct Rx, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (500mglabel)

The image shows a yellow and white packaging label for NABUMETONE 500 mg tablets with 30 tablets per container. It notes the product is generic for RELAFEN and each tablet contains 500 mg of nabumetone. The label includes cautionary information about drowsiness and keeping the product out of reach of children. It is packaged and distributed by Direct Rx in Alpharetta, GA, with a discard date of 12/16.*

FDA Label Image

Image Description (750mglabel)

NABUMETONE 750mg tablet packaging label contains 30 tablets, labeled as generic for RELAFEN. The label indicates each tablet contains nabumetone USP 750mg. It is packaged and distributed by Direct Rx, Alpharetta, GA 30005. The label also includes lot and expiration information along with warnings about potential drowsiness or dizziness.*

FDA Label Image

Image Description (Chart)

A table listing side effects categorized into serious and other side effects. Serious side effects include heart attack, stroke, high blood pressure, heart failure from fluid retention, kidney problems including failure, bleeding and ulcers in the stomach and intestine, anemia, life-threatening skin and allergic reactions, liver problems including failure, and asthma attacks. Other side effects include stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.*

FDA Label Image

Image Description (Chart2)

A data table listing generic NSAID names alongside their corresponding trade names. Examples include Celecoxib with Celebrex, Diclofenac with Cataflam and Voltaren, and Nabumetone with Relafen. The table also features a footnote about Vicoprofen containing ibuprofen and related usage warnings.*

FDA Label Image

Image Description (Graph)

A line graph showing plasma concentrations of nabumetone active metabolite (6MNA) at steady state following once-daily dosing of 1000 mg and 2000 mg doses. The y-axis represents concentration, and the x-axis represents time in hours. Shaded regions indicate ±2 standard deviation ranges for the two doses.*

FDA Label Image

Image Description (Moleculestructure)

Chemical structure of the active ingredient Nabumetone, showing a methoxy-substituted naphthalene ring linked to a ketone-containing side chain.*

FDA Label Image

Pillimage750mg

NABUMETONE tablet supplied by Direct Rx, imprinted with the numbers '99' on one side and '16' on the other. The tablet is oblong and light brown in color, with an approximate length of 19 mm based on the visible scale. No additional labeling or packaging information is visible in the image.*

FDA Label Image

Image Description (Structure2)

Chemical structure diagram of the active ingredient Nabumetone, showing its molecular configuration with methoxy and carboxylic acid functional groups attached to a naphthalene ring system.*

FDA Label Image

Image Description (Table1)

A data table titled 'Mean Pharmacokinetic Parameters of Nabumetone Active Metabolite (6MNA) at Steady State Following Oral Administration of 1,000 mg or 2,000 mg Doses of Nabumetone.' It presents pharmacokinetic values including Tmax, t1/2, CLss/F, and Vdss/F for young adults and elderly groups at specified doses.*

FDA Label Image

Image Description (Table2)

A table showing the metabolic profile of nabumetone. It lists different metabolites including unchanged nabumetone, 6-methoxy-2-naphthylacetic acid, and their conjugates, with corresponding percentages of dose recovered, totaling 73% dose.*

FDA Label Image

Image Description (Table3)

A data table titled Table 2 showing clinical double-blinded and open-labeled trials of Nabumetone in osteoarthritis (OA) and rheumatoid arthritis (RA). It displays doses of Nabumetone (500 mg, 1,000 mg, 1,500 mg, 2,000 mg), number of patients for OA and RA, and mean/mode duration of treatment in years for OA and RA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.